Bristol-Myers Squibb Co

Pfizer reported Q1 adjusted EPS of $0.75 on $14.45B revenue, beating estimates. Growth in Eliquis and Padcev offset COVID declines, but patent cliff remains a key concern.

Eli Lilly will purchase Kelonia Therapeutics in a deal worth up to $7 billion, gaining an in vivo CAR-T therapy currently in Phase 1 trials for multiple myeloma.

Eli Lilly will purchase Kelonia Therapeutics in a deal valued at up to $7 billion, gaining an experimental in-body CAR-T therapy for blood cancer. Lilly shares rose 2.5% on the news.

Johnson & Johnson exceeded Wall Street's first-quarter forecasts, driven by strong performance from Darzalex and Tremfya. The company raised its full-year 2026 sales guidance.

Merck has agreed to acquire Terns Pharmaceuticals in a $6.7 billion all-cash deal. Terns shares traded at $52.86, close to Merck's $53-per-share offer, as investors weigh the deal's completion.

Pfizer shares declined 1% to $26.60 Friday after GSK secured expanded FDA approval for its RSV vaccine, challenging Pfizer's market position. Encouraging clinical results for blood thinner Eliquis helped cushion the drop.

Johnson & Johnson has submitted an application to European regulators to expand the use of its myeloma drug Tecvayli as a monotherapy after just one prior treatment. This follows recent U.S. approval for a Tecvayli combination and is supported by trial data showing a 71% reduction in disease progression risk.

Reviva Pharmaceuticals Holdings has implemented a 1-for-20 reverse stock split to boost its share price and avoid a Nasdaq delisting, with a critical compliance deadline of March 27. The company also faces financing challenges for an additional Phase 3 trial of its schizophrenia drug candidate, brilaroxazine.

Eli Lilly's stock declined 0.9% as investors assessed the company's strategic moves into cell therapy and Chinese drug development. The market is weighing increased pipeline spending against intensifying competition in obesity treatments.

Eli Lilly shares declined 1.3% in after-hours trading after announcing a $2.4 billion acquisition of Orna Therapeutics. Investors are monitoring the deal's impact on Lilly's pipeline and upcoming regulatory decisions.